Elliott paid down debt, settled lawsuits, sold off a neurovascular business, and built a senior leadership team -- but failed to ignite growth. Now what: Elliott, 61, will help search for his replacement and remain on the board. He stated that the company is positioned for growth and much of the turnaround work will be complete by the time he departs at year-end. Boston Scientific will be competing for CEO talent with larger competitor Medtronic (NYSE: MDT), which adds to the uncertainty surrounding Elliott's unexpected departure. Interested in more info on BSX?